KR20060046978A - Composition for protecting and improving viral diseases comprising chaga mushroom extracts - Google Patents

Abstract

The present invention relates to a composition for the prevention and improvement of viral diseases containing chaga extract as an active ingredient, more specifically, human immunodeficiency virus (HIV), herpes simplex virus (HSV), PMWS virus, PRRS A composition comprising chaga extract having good antiviral activity against viruses, PED viruses, TGE viruses, parvoviruses and distemper viruses.

The chaga extract of the present invention is a natural-derived material, and exhibits excellent antiviral activity against various viruses without showing toxicity and side effects, so that the composition comprising the same is effective and safe for the prevention and improvement of viral diseases for food or feed. It can be usefully used as a composition.

Chaga, Antiviral, HIV, HSV

Description

Composition for Protecting and Improving Viral Diseases Comprising Chaga Mushroom Extracts             

Figure 1 illustrates the extraction process of chaga extract of the present invention.

The present invention relates to a composition for the prevention and improvement of viral diseases containing chaga extract as an active ingredient, more specifically, human immunodeficiency virus (HIV), herpes simplex virus (HSV), PMWS virus, PRRS A composition comprising chaga extract having good antiviral activity against viruses, PED viruses, TGE viruses, parvoviruses and distemper viruses.

The virus causes various diseases, of which human immunodefficiency virus (HIV) is known to cause AIDS in the human body, which is emerging as an international challenge. Barre, F. et al., Science , 220: 868, 1983). AIDS is a spreading immunosuppressive disease that causes fatal opportunistic infections and malignancies. HIV is largely classified into two types, HIV-1 and HIV-2, and HIV-1 is further classified into two groups, group M and group O. Group M is the most common worldwide, and group O is mainly distributed in western Africa. HIV-2 is mainly found in West Africa, but is gradually spreading around the world (Charneau, P. et al., Virology , 205: 247, 1994; Gould, K. et al., Lancet , 348: 680, 1996).

On the other hand, considerable efforts have been made to devise effective therapies for AIDS, but there are no antiviral therapeutic drugs for AIDS yet. Attempts to develop such drugs have focused on several stages of the HIV virus life cycle. Since harmful side effects may occur when interfering with host cell proteins, various viral targets have been proposed to interfere with the life cycle of the HIV virus. For example, 2,3-dideoxynucleosides showing antagonistic activity against the HIV virus are proposed. Numerous reverse-transcriptase-targeting agents have been developed, including seed analogs such as azidothymidine (AZT), ddI (2 ', 3'-dideoxy inosine), ddC (2', 3'-dideoxycytidine), d4T (Mitsuya, H. et al., Science , 249: 1533, 1991). Targeting reverse transcriptases such as azidomidine (AZT), lamivudine (3TC), dideoxyinosine (ddI), and dideoxycytosine (ddC) in combination with HIV protease inhibitors in novel treatment regimens for the HIV-1 virus It was found that the anti-HIV virus complex compound showed a much improved effect compared to AZT alone. However, long-term use of a mixture of these drugs is likely to cause toxicity to the bone marrow, and long-term cytotoxic therapies may be due to the action of biocidal and inhibitory factors, mainly rantes, MIP-1α and MIP-1β. Release inhibits CD8 + T cells, which are essential for the regulation of the HIV virus. In addition, long-term antiretroviral chemotherapy is likely to cause HIV mutations with partial or complete resistance (Blazevic, V. et al., AIDS Res ., 11: 1335, 1995; Cocchi, F. et al. , Science , 270: 1811, 1995).

Herpes simplex virus (hereinafter referred to as 'HSV'), which is pathogenic to humans, belongs to the alpha subgroup of the herpes virus family, and is classified into type 1 and type 2, and type 1 is used for oral cavity and face. It is mainly a lesion of the pidgin, type 2 causes the genitals and anus, and the disease, ranging from very pharmaceutical lesions to fatal lesions. The main characteristic lesions are stomatitis, gingivitis, herpes eczema, aseptic meningitis, herpetic keratoconjunctivitis, acute ulcers, esophagitis, primary atypical pneumonia and fetal encephalitis. HSV is easily transmitted from simple contamination such as household tools necessary for eating, in addition to infection by close contact between human secretions and the opposite sex, and more than 85% of adults are incubated in the body, making it easy to infect fetuses and newborns with weak immunity. (Dressman, GR et al., Nature , 283: 591, 1980). However, the development of vaccines against HSV is still inadequate.

On the other hand, PMWS is a post-weaning multisystemic wasting syndrome of main weaning pigs.The main symptoms are appetite deficiency, systemic weakness, dyspnea, jaundice due to weight loss, and sometimes diarrhea, cough, and sometimes the central nervous system It is a consumable disease that is disordered and is characterized primarily by the development of multiple lesions in the general lymphatic system (Harding, JC, Proc. West. Can. Assoc. Swine. Pract. , 58: 503, 1996). Although the exact cause of PMWS is still controversial, PCV2 is recognized as the primary cause of PMWS because the infection of porcine circovirus type 2 (PCV2) has been common in PMWS. Recently, in addition to PMWS, various disease syndromes such as reproductive disorders, swine dermatitis syndrome (PDNS), swine respiratory disease complex infection (PRDC), proliferative necrotic pneumonia (PNP), congenital tremors, etc. It has been reported that PCV2 is associated with disease.

Porcine reproductive and respiratory syndrome (PRRS) is caused by an enveloped positive-stranded virus with a membrane of arteririridae (Snijder, EF and Meulenberg, JJM, J. of General Virology , 79: 961, 1998). The PRRS virus is infected by breathing, achievement, bite wounds or needles, and multiplies in the macrophage of the mucous membranes, lungs or local areas. Subclinically the disease results in degradation or persistent infection, and the persistently infected animal releases the virus in the fluids, blood, feces, urine and semen of the oral / pharyngeal.

The causative agent of porcine ephidemic diarrhea (PED) is the swine epidemic diarrhea virus belonging to the coronavirus, a coronavirus that is not antigenically related to the TGE virus. The virus propagates in epithelial cells of the small intestine and colon and mesenteric lymph nodes. The PED virus is combined with some transmissible gastroententis (TGE) to increase the damage, and is caused by sows of pigs regardless of age. The pathogen of porcine infectious gastroenteritis (TGE) is a TGE virus belonging to the coronavirus and is easily killed by sunlight, high temperature and is easily inactivated in formalin, caustic soda, iodine solution, ether and chloroform. The development of TGE is almost similar to that of PED, but it does not occur in hot seasons, but mainly in winter.

Canine parvovirus (CPV) belongs to the genus parvovirus (pravoviridae), parvovirus (parvovirus) and belongs to a kind of feline parvovirus (feline parvovirus). The main symptoms caused by parvovirus are severe after 5 days of oral infection. When susceptible dogs are exposed to the virus, 100% of the dogs are infected, about 75% of them are non-infectious, and 25% have high mortality.

In addition, canine distemper virus (CDV) infection is a highly infectious acute or subacute recessive disease in predators, including dogs, and canine, dogs, foxes, wolves, Raccoon is a viral disease that shows high morbidity and mortality due to infection with predators such as raccoons, pandas and weasels, weasels, badgers, skunks and ferrets. The pathogen of canine distempervirus infection is a distemper virus, which belongs to the family of paramyxoviridae, morbillivirus, and has various clinical symptoms. appear. There are few treatments for canine distemper virus infection, and serum preparations are sometimes used as serum therapy, but they are not practical because they are easy to miss.

Chaga, on the other hand, occurs in Betula sp. , In particular in birch ( Betula platyphylla var. Japonica). It is a semi-reflective parasitic mushroom that is attached to a birch tree like a black rock mass, and the birch tree gradually dies as the mass grows larger. Chaga mushroom, unlike other medicinal mushrooms that break down the wood of the dead tree as a nutrient source, has lived in the birch for 10 to 15 years, absorbs the rich nutrients, and has been decomposed and stored for a long time. have. Chaga's efficacy includes anti-tumor activity, lowering blood sugar, removing free radicals, lowering blood pressure, lowering cholesterol, intestinal action, and improving atherosclerosis.

In recent years, unlike chemicals that cause various side effects, the drug has been recognized for thousands of years, and active research is being conducted to obtain active ingredients from natural products with low toxicity and side effects. As an example, Korean Patent Application No. 10-2003-0011238 discloses antiviral activity against hepatitis B virus (HBV) and human immunodeficiency virus (HIV) of African Ganoderma lucidum extract, and Korean patent application 10-2003-0024419 discloses a composition for treating HIV / AIDS patients containing chlorosis. In addition, U.S. Patent No. 5,178,865 discloses the anti-HIV activity of ten herbal medicines such as Huangyan, Cheongung, Isolum Tree, Daecheong, Dansam, Sukjeong, Sejugapi, Bovine, Mokyang, and Indong. No. discloses a composition for the treatment of viral infections, including jago, smuttweed, cheonnwanggwang, hojanggeun, duct bridge and trekking chamber.

However, none of the literature discloses any teaching about the antiviral activity of chaga extract.

Therefore, the inventors of the present invention are new to the non-toxic and ideal efficacy of chaga mushroom human immunodeficiency virus (HIV), herpes simplex virus (HSV), PMWS virus, PRRS virus, PED virus, TGE virus, parvovirus and distemper virus One antiviral effect was identified and the present invention was completed.

After all, the main object of the present invention is to provide a food or feed composition for the prevention and improvement of viral diseases containing chaga extract having antiviral activity as an active ingredient.

In order to achieve the above object, the present invention provides a food composition for the prevention or improvement of viral diseases, including chaga mushroom extract having antiviral activity and a food supplement acceptable food supplement.

The present invention also provides a feed composition for the prevention or improvement of viral diseases comprising the chaga extract.

In the present invention, the extract may be characterized in that the extract soluble in C ₁ ~ C ₄ lower alcohol, water or a mixed solvent thereof, preferably 50 to 99% ethanol.

In the present invention, the extract may be obtained by adding a lower alcohol of C ₁ ~ C ₄ to chaga or dried products thereof, and reflux extraction at room temperature for 12-36 hours, followed by vacuum filtration and concentration under reduced pressure.

In the present invention, the virus is human immunodeficiency virus type 1 (HIV-1), human immunodeficiency virus type 2 (HIV-2), herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2), post-weaning multisystemic wasting syndrome (PMWS) virus, porcine reproductive and respiratory syndrome (PRRS) virus, porcine ephidemic diarrhea (PED) virus, transmissible gastroententis (TGE) virus, carnine parvo (CP) virus, or CD (carnine distemper) can be characterized as a virus.

Hereinafter, the present invention will be described in detail.

Chaga mushroom extract of the present invention can be obtained as follows.

After purchasing and pulverizing the chaga mushroom of the present invention, a volume of water and a C ₁ ~ C ₄ such as methanol, ethanol, butanol, etc., which are about 2 to 10 times, preferably about 3 to 6 times the weight of the chaga mushroom sample A polar solvent of lower alcohol or a mixed solvent having a mixing ratio of about 1: 0.1 to 1:10, preferably 50 to 99% of ethanol at room temperature for about 1 to 5 weeks, preferably 1 to 5 After extracting by using an extraction method such as hot water extraction, cold needle extraction, reflux cooling extraction or ultrasonic extraction for one day, the supernatant can be collected and concentrated under reduced pressure to obtain crude chaga extract and residue. In addition, a polar solvent of water and a C ₁ to C ₄ lower alcohol, such as methanol, ethanol, butanol, or the like, having a volume of about 2-10 times, preferably about 3-6 times, the sample weight in the chaga residue, or These are mixed solvents having a mixing ratio of about 1: 0.1 to 1:10, preferably hot water extraction, cold needle extraction and reflux for about 12 hours to 5 days, preferably 12 hours to 2 days at 50 to 100 ° C with water. After extraction using an extraction method such as cooling extraction or ultrasonic extraction, the mixture is collected into a supernatant, concentrated under reduced pressure, and then centrifuged by adding 0.1-10 times, preferably 1-10 times, ethanol to the obtained product. Lyophilized under dialysis and reduced pressure may yield chaga extract.

In addition, the chaga extract obtained above may be further subjected to a conventional fractionation process (Harborne, JB, A guide to modern techniques of plant analysis, 3: 6, 1998).

Searching for the antiviral effect of chaga extract obtained by the above method, it can be seen that it shows excellent antiviral activity against HIV, HSV, PMWS virus, PRRS virus, PED virus, TGE virus, parvovirus and distemper virus. there was. In addition, chaga mushroom has been used as a herbal medicine for a long time, the extracts of the present invention extracted therefrom also have no problems such as toxicity and side effects.

The composition containing chaga extract having the antiviral activity of the present invention can be usefully used as a food or feed composition for the prevention and improvement of viral diseases.

Chaga extract of the present invention can be added to a variety of foods for the prevention and improvement effect of viral diseases. Examples of the food to which the extract can be added include various foods, beverages, gums, teas, vitamin complexes, and health functional foods.

The health functional beverage composition of the present invention is not particularly limited to other ingredients except for having the extract as an essential ingredient in the indicated ratio, and may contain various flavors or natural carbohydrates, etc. as additional ingredients, as in general beverages. Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose and the like; And conventional sugars such as polysaccharides such as dextrin, cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As flavoring agents other than those described above, natural flavoring agents (tauumatin, stevia extract (e.g., Rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used. The proportion of natural carbohydrates is generally about 1-20 g, preferably about 5-12 g per 100 ml of the composition of the present invention.

In addition to the above, the extract of the present invention includes various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, coloring and neutralizing agents (such as cheese and chocolate), pectic acid and salts thereof, alginic acid and its Salts, organic acids, protective colloidal thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated beverages, and the like. In addition, the extracts of the present invention may contain flesh for the production of natural fruit juices and fruit juice beverages and vegetable beverages. These components can be used independently or in combination. The proportion of such additives is not so critical but is usually selected in the range of 0 to 20 parts by weight per 100 parts by weight of the extract of the present invention.

Hereinafter, the present invention will be described in more detail with reference to Examples. These examples are only for illustrating the present invention, it will be apparent to those skilled in the art that the scope of the present invention is not to be construed as being limited by these examples.

Example 1 Preparation of Chaga Extract

After purchasing and grinding the dried chaga, 95% ethanol was added to the chaga powder, and then refluxed at room temperature for 24 hours, followed by vacuum filtration to recover the supernatant. This process was repeated three times to collect the supernatant, and then concentrated under reduced pressure to obtain chaga extract and residue. The chaga extract was named "CHP7" and used in the following experiment.

Example 2: Preparation of Chaga Extract

Water was added to the chaga residue obtained in Example 1, followed by reflux extraction at 100 ° C. for 3 hours, and then the supernatant was recovered by vacuum filtration. This process was repeated three times to collect the supernatant and then filtered, and centrifuged by adding four times 95% ethanol to the filtrate obtained. The obtained product was dissolved in water, dialyzed and lyophilized under reduced pressure to obtain chaga extract. The chaga extract obtained was named "C2" and used in the following experiment.

Example 3: anti-HIV (human immunodefficiency virus) effect

In order to determine the anti-HIV effect of the chaga extract obtained in Examples 1 and 2 were tested as follows using the CPE inhibition method.

Specifically, chaga extract (CHP7 and C2) is dissolved in 100% DMSO at 10 ~ 40mg / ㎖, dissolved in PBS solution and stored at -20 ℃ and diluted 1 times, twice the test concentration in the culture on the day of the experiment The concentration of DMSO in the wells was 0.5% and 1%, respectively. First, centrifuge the MT-4 cells, remove the supernatant, inoculate the cell precipitate with 100 CCID ₅₀ (50% cell culture inhibitory dose), and add RPMI 1640/10%. Diluted to 10 ⁵ cells / ml, mock-infected was used as it is without the addition of virus. Add 100 μl of cell diluent per well to the plate containing the double diluted drug, incubate for 5 days in a CO ₂ incubator at 37 ° C., and then measure the number of surviving cells using MTT screening with microscopy. The antiviral effect and toxicity of the drugs were measured in comparison with the cell control. In other words, the number of surviving cells in the mock-infected wells, in which the non-virus-inoculated cells were added to the drug, was compared to the CC ₅₀ (50% cytotoxic conentration) compared to the cell control wells without the drug. To determine the toxicity of the drug was determined by), the concentration of the drug to survive 50% of virus-infected cells was determined by EC ₅₀ (50% effective concentration) to measure the antiviral effect.

As a result, as shown in Table 1, chaga extract CHP7 of the present invention showed high antiviral activity against HIV-1, C2 also showed a significant antiviral effect against HIV-1. .

Cytotoxicity (CC ₅₀ ) Antiviral effect (EC ₅₀ ) SI HIV-1 HIV-2 HIV-1 HIV-2 CHP7 > 200.0 3.73 28.62 > 53.60 > 6.99 C2 381.80 16.00 129.27 24 3

Selectivity index (SI) = CC ₅₀ / EC ₅₀

Example 4: anti-HSV (herpes simplex virus) effect

In order to determine the anti-HSV effect of the chaga extract obtained in Examples 1 and 2 were tested as follows using the CPE inhibition method.

That is, chaga extract (CHP7 and C2) is dissolved in 100% DMSO at 10 ~ 40mg / ㎖, and then dissolved in PBS solution and stored at -20 ℃ and diluted 1 times, twice the test concentration in the culture on the day of the experiment The concentration of DMSO in the wells was less than 0.5% and 1%, respectively. First, Vero cells were propagated in a 96 well plate, and then 100 µl of each virus was inoculated into each well to inoculate 100 CCID ₅₀ of the virus diluted with DME / 2% FBS culture medium, and then adsorbed at 37 ° C. for 1 hour. Was removed. The drug was diluted with each concentration in duplicate to a drug concentration of 50% to survive the cells were added one by 100㎕ to each well, and cultured at 37 ℃, CO ₂ incubator for three days and then MTT assay with EC ₅₀ Decided. In addition, in order to evaluate the toxicity of the drug, the virus-free culture medium was added to the cells (mock-infected), treated with the same method as the cells inoculated with the virus, and then the drug was detected using the MTT detection method. The number of surviving cells in each of these added mock-infected wells was compared to the cell control wells in which no drug was added to determine the concentration of drug ₅₀ CC to kill the cells. As standard drugs, acyclovir (cyclosine) and cytosine 2-d-arabinofuranoside (Sigma) were used.

As a result, as shown in Table 2, chaga extracts CHP7 and C2 of the present invention showed excellent anti-HSV-2 activity without cytotoxicity, compared to the acyclober used for the treatment of herpes virus, and to HSV-1 It was confirmed that also showed a significant antiviral effect. In addition, compared to cytosine 2-d-arabinofuranoside, chaga extract of the present invention showed significantly improved antiviral effect in both HSV-1 and HSV-2.

Cytotoxicity (CC ₅₀ ) Antiviral effect (EC ₅₀ ) SI HSV-1 HSV-2 HSV-1 HSV-2 CHP7 > 300.0 4.69 4.55 > 63.97 > 65.93 C2 117.18 1.69 2.05 > 69.34 57.16 Acycrober (ACV) > 10.00 0.07 1.68 > 149.25 > 5.95 Cytosine 2-d-arabinofuranoside (ARA-C) 1.72 0.06 > 1.72 30.71 <1

Example 5: Post-weaning multisystemic wasting syndrome virus (PMWSV) effect

In order to examine the bactericidal effect of PMWS virus of chaga extract obtained in Example 1, PK 15 cell line was used as a cell line of porcine circovirus type 2 (PCV2), a causative agent of PMWS, and a positive control virus. PCV2 strain DR673 (10 ^6.0 TCID ₅₀ /0.1ml by PCR) was used.

After adding 1 ml of chaga extract (CHP7) sample and 1 ml of virus solution, sterilized hard water was added to make 8 ml, and the mixture was diluted 1:10 times. 1 ml of the virus solution was added to 1 ml of the diluted solution, sterilized hard water was added to make 8 ml, and the mixture was diluted 1:50 times. The same procedure was repeated to obtain dilutions of 500, 800, 1,000, 1,200, 1,500, and 2,000 times. The resulting dilutions were incubated at 4 ° C. for 30 minutes, and three 96-well plates containing PCV from which PK-15 cells had been removed were removed from the medium and washed with PBS. 100 μl of each dilution (800, 1000, 1200, 1500, 2000 times) was inoculated three times in a 96-well plate, followed by incubation at 37 ° C. for 1 hour, and the negative control group was inoculated with 100 μl of culture medium. . After incubation, the dilutions were removed and washed three times with PBS. After incubating 50 μl of 300 mM D-glucosamine in each well of the plate, the culture solution was incubated for 15 minutes, and then the virus solution was removed and washed three times with PBS. 200 μl of the culture medium was added to each well of the plate from which the virus solution was removed, followed by further incubation for 48 hours at 37 ° C., and then the bactericidal effect against PMWS virus was measured using the IFA method. That is, after removing the culture medium from each well, a 96-well plate was fixed using ethanol for 2 hours or more at -20 ° C, and then ethanol was removed and the plate was dried for 30 minutes. 100 μl of PCV positive serum was added to each well, incubated for 2 hours at 37 ° C., and then serum was removed, washed three times with 100 μl of PBS, followed by 50 μl fluorescein conjugated anti-pig IgG ( Fluorescein conjugated anti-swine IgG) was added to each well and incubated at 37 ° C. for 1 hour. Each well was washed once again and the plates were observed using a fluorescence microscope (10X objective lens).

As a result, the chaga extract of the present invention was confirmed to effectively sterilize the PCV2 virus up to 1,000 times the concentration in 1% organic matter and 5% organic matter conditions (see Table 3).

1% organic matter 5% organics 800 U U 1,000 U U 1,200 Null Null 1,500 Null Null 2,000 Null Null

Example 6: Antiviral Effect

In order to measure the PRRS, PED, TGE, CP and CD virus bactericidal effect of the chaga extract obtained in Example 1, the cell line and the published virus of Table 4 were used. Experiments on the bactericidal effect of chaga extract (CHP7) according to the virus disinfectant efficacy test guideline (Korea Veterinary Drug Association: http://kahpa.or.kr/index_k.htm, prescribed in Annex 2) Was performed.

Specifically, MEM [minimum essential medium; 10% FBS to the cell line for each virus; L-glutamine, HEPES buffer, non-essential amino acids, NaHCO ₃ , antibiotics] media were used for subculture, using live virus during subculture, and harvesting at the point of maximum virus proliferation and shortly before use. And stored in ice water for a while. Before reacting the test sample with the virus, it was diluted 400 times, 500 times, 600 times, 700 times, 800 times, 900 times, 1000 times, and 1200 times according to the dilution method of the disinfectant in the disinfectant efficacy test guideline. 1.0 ml of the expanded 4 ° C. virus solution was mixed with 19.0 ml of 1% organic matter dilution at 4 ° C., 2.5 ml of the mixed solution was removed at 1 minute intervals, and placed in a test tube containing the same amount of sample dilution at 4 ° C., followed by mixing. The reaction was carried out for exactly 30 minutes at the same temperature, and was mixed every 10 minutes in the middle of the reaction. The control group used hard or distilled water instead of the sample. After the reaction was completed, 1.0 ml was immediately taken out, mixed in a neutralizing medium of 37 ° C. in the same amount, and then diluted. The neutralization reaction solution was diluted and the appropriate amount was inoculated into cells to measure the virus content. To determine the proliferation of the virus, the medium was removed from the monolayer plate to be inoculated with the sample, washed with PBS, and inoculated three times with 100 µl of the diluted sample in each well of the plate. At this time, the negative control group was added 200µl of the media component, the plate was incubated for 72 hours at 37 ℃, and observed the growth of the virus using the cytopathic effect (CPE). The Kaerber method was used for the virus content. The virus concentration of the pathogen control group was compared with the virus content of the sample treatment group, and the dilution concentration for which 10 ⁴ TCID ₅₀ inactivation was recognized was used as an effective concentration. The median of the results was taken.

As a result, as shown in Table 5, chaga extract (CHP7) of the present invention effectively sterilize PRRS virus, PED virus, TGE virus and canine parvovirus (CPV) to 1: 700 concentration under 5% organic matter conditions I could confirm that. In addition, it was confirmed that dog distemper virus (CDV) was effectively sterilized to a concentration of 1: 400.

Cell line Disclosure Virus PRRS virus MARC-145 cells VR-2332 strain, 10 ^5.0 TCID ₅₀ / ml PED virus Vero cells KPEDV-9 strain, 10 ^5.5 TCID ₅₀ / mL TGE virus ST cells Pyungtak-40 strain, 10 ^5.5 TCID ₅₀ / ml CP virus (canine parvovirus) CRFK cells C-780916 strain, 10 ^5.0 TCID ₅₀ / mL CD Virus (Dog Distempervirus) Vero cells Lederle strain, 10 ^5.0 TCID ₅₀ / ml

Dilution factor Antiviral Effective Concentration PRRS PED TGE CP CD 1: 400 U U U U U 1: 500 U U U U radish 1: 600 U U U U radish 1: 700 U U U U radish 1: 800 radish radish radish radish radish 1: 900 radish radish radish radish radish 1: 1,000 radish radish radish radish radish 1: 1,200 radish radish radish radish radish

Having described the specific part of the present invention in detail, it is obvious to those skilled in the art that such a specific description is only a preferred embodiment, thereby not limiting the scope of the present invention. something to do. Thus, the substantial scope of the present invention will be defined by the appended claims and their equivalents.

As described in detail above, the chaga extract of the present invention is a substance derived from natural products, and exhibits excellent antiviral activity against various viruses without showing toxicity and side effects, and the composition comprising the same prevents and improves viral diseases. It can be usefully used as an effective and safe food or feed composition.

Claims (8)

A food composition for preventing or ameliorating a viral disease, comprising a chaga extract having antiviral activity and a food acceptable additive. According to claim 1, wherein the extract is a composition characterized in that the extract soluble in C ₁ ~ C ₄ lower alcohol, water or a mixed solvent thereof. The method of claim 1, wherein the extract is refluxed for 12 to 36 hours at room temperature was added to the lower alcohol of C ₁ ~ C ₄ to Chaga or a dried substance is extracted, and then, the composition, characterized in that which is obtained by concentration under vacuum filtration and pressure. The method of claim 1, wherein the virus is human immunodeficiency virus type 1 (HIV-1), human immunodeficiency virus type 2 (HIV-2), herpes simplex virus type 1 (HSV-1), herpes simplex virus 2 Type (HSV-2), post-weaning multisystemic wasting syndrome (PMWS) virus, porcine reproductive and respiratory syndrome (PRRS) virus, porcine ephidemic diarrhea (PED) virus, transmissible gastroententis (TGE) virus, carnine parvo (CP) virus Or a CD (carnine distemper) virus. Feed composition for the prevention or improvement of viral diseases comprising chaga extract of claim 1. The composition according to claim 5, wherein the extract is a C ₁ ~ C ₄ lower alcohol, water or an extract soluble in a mixed solvent thereof. The method of claim 5, wherein the extract is refluxed for 12 to 36 hours at room temperature was added to the lower alcohol of C ₁ ~ C ₄ to Chaga or a dried substance is extracted, and then, the composition, characterized in that which is obtained by concentration under vacuum filtration and pressure. The method of claim 5, wherein the virus is human immunodeficiency virus type 1 (HIV-1), human immunodeficiency virus type 2 (HIV-2), herpes simplex virus type 1 (HSV-1), herpes simplex virus 2 Type (HSV-2), post-weaning multisystemic wasting syndrome (PMWS) virus, porcine reproductive and respiratory syndrome (PRRS) virus, porcine ephidemic diarrhea (PED) virus, transmissible gastroententis (TGE) virus, carnine parvo (CP) virus, or A composition characterized in that the CD (carnine distemper) virus.

Images